U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBusiness Wire • 02/12/25
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery PlatformBusiness Wire • 02/11/25
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)Business Wire • 02/10/25
Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?Zacks Investment Research • 02/10/25
Compared to Estimates, Pfizer (PFE) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/04/25
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFSZacks Investment Research • 02/04/25